What You Should Know
- The Raise: Clinical-stage medical device company Sonire Therapeutics has announced an $18M Series A financing round. The round was led by Santé Ventures, with participation from Fast Track Initiative (FTI), Nomura SPARX Investment, and SBI Investment.
- The Technology: Sonire has developed a proprietary High-Intensity Focused Ultrasound (HIFU) therapy system for the non-invasive thermal ablation of solid tumors.
- The Clinical Target: The company is initially focusing on pancreatic cancer, a notoriously lethal disease with a 5-year survival rate of only 12% and very limited local therapy options. The device received an FDA Breakthrough Device Designation in 2024.
- The Workflow Disruption: Unlike conventional ultrasound-guided HIFU systems, Sonire’s solution provides clear real-time visualization, requires no anesthesia, and can be performed on an outpatient basis in roughly 20 minutes. It also only requires one physician to administer, drastically lowering the staffing burden.
A New Approach to Lethal Solid Tumors
Pancreatic cancer remains a devastating diagnosis with a 5-year survival rate of just 12%. Current local therapy options are limited, leaving a high unmet medical need for patients. Sonire’s proprietary HIFU system is designed to prolong survival when combined with chemotherapy, offering a safer alternative to traditional surgery or radiation.
Unlike conventional ultrasound-guided systems, Sonire’s technology provides several key clinical advantages:
- Enhanced Visualization: Patented noise-cancellation and cavitation bubble visualization allow for clear, real-time imaging of the treatment site.
- Outpatient Convenience: The procedure typically takes only 20 minutes, requires no anesthesia, and is performed on an outpatient basis.
- Operational Efficiency: The system is robot-assisted and requires only one physician to administer, reducing the staffing burden and cost for hospitals.
- Precision Engineering: Advanced multi-focus scanning enables precise thermal ablation of tumors.
Landmark Clinical Progress
The funding will support the completion of the SUNRISE-I randomized controlled trial in Japan. This study is the world’s first of its kind to evaluate HIFU combined with chemotherapy specifically for pancreatic cancer. Early foundational work using a prototype system demonstrated a 66% disease control rate in patients with advanced pancreatic and biliary tract cancers.
With 25 issued patents and its 2024 FDA Breakthrough Device Designation, Sonire is now expanding its corporate footprint from Tokyo to its new headquarters in Palo Alto, California.
Scaling for Global Impact
“Our goal is to deliver a new standard of care that gives patients more time and better quality of life,” said Tohru Satoh, President and CEO of Sonire Therapeutics. As the company prepares for U.S. clinical and regulatory milestones, it aims to prove that next-generation acoustic engineering can solve the core challenges of precision and workflow that have historically limited the field of oncology.
